tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Zylox-Tonbridge Reports Strong Revenue Growth in H1 2025

Story Highlights
Zylox-Tonbridge Reports Strong Revenue Growth in H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ).

Zylox-Tonbridge Medical Technology Co., Ltd. reported a significant increase in revenue and profit for the first half of 2025, with a 31.7% rise in revenue compared to the same period in 2024. This growth was driven by high sales in both neurovascular and peripheral vascular interventional devices, with notable contributions from established products and the successful launch of new products across hospitals nationwide.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. is a company based in China that specializes in the development, production, and commercialization of medical devices, particularly focusing on neurovascular and peripheral vascular interventional products.

Average Trading Volume: 649,977

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.41B

For an in-depth examination of 2190 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1